Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KUMUDHA BALAKRISHNAN and VARSHA V GANDHI.
KUMUDHA BALAKRISHNAN
Connection Strength
8.537
VARSHA V GANDHI
  1. Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. Oncotarget. 2016 Jun 28; 7(26):39458-39472.
    View in: PubMed
    Score: 0.556
  2. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014 Dec; 16(12):1036-46.
    View in: PubMed
    Score: 0.499
  3. Uncoupling endoplasmic reticulum stress and autophagy: a potential implication for chronic lymphocytic leukemia therapy. Leuk Lymphoma. 2013 Dec; 54(12):2581-3.
    View in: PubMed
    Score: 0.465
  4. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 2013 Oct; 31(5):1384-94.
    View in: PubMed
    Score: 0.455
  5. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):458-66.
    View in: PubMed
    Score: 0.451
  6. Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2013 May; 54(5):1097-100.
    View in: PubMed
    Score: 0.427
  7. CCL2 in chronic lymphocytic leukemia: a macro in microenvironment? Leuk Lymphoma. 2012 Oct; 53(10):1849-50.
    View in: PubMed
    Score: 0.419
  8. Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2012 Apr; 21(4):409-23.
    View in: PubMed
    Score: 0.413
  9. The micros in harmony: microRNA and microenvironment. Leuk Lymphoma. 2011 Sep; 52(9):1626-9.
    View in: PubMed
    Score: 0.394
  10. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91.
    View in: PubMed
    Score: 0.363
  11. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009 Jan 01; 113(1):149-53.
    View in: PubMed
    Score: 0.325
  12. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2008 Sep 01; 112(5):1971-80.
    View in: PubMed
    Score: 0.319
  13. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Semin Oncol. 2007 Dec; 34(6 Suppl 5):S8-12.
    View in: PubMed
    Score: 0.307
  14. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006 Oct 01; 108(7):2392-8.
    View in: PubMed
    Score: 0.277
  15. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res. 2005 Sep 15; 11(18):6745-52.
    View in: PubMed
    Score: 0.263
  16. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 2005 Jun 01; 105(11):4455-62.
    View in: PubMed
    Score: 0.253
  17. Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica. 2021 02 01; 106(2):495-512.
    View in: PubMed
    Score: 0.191
  18. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia. 2017 Oct; 19(10):762-771.
    View in: PubMed
    Score: 0.151
  19. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res. 2017 12; 15(12):1692-1703.
    View in: PubMed
    Score: 0.151
  20. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. 2017 Mar 07; 8(10):16259-16274.
    View in: PubMed
    Score: 0.146
  21. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3734-3743.
    View in: PubMed
    Score: 0.144
  22. Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2016 10 13; 9(1):110.
    View in: PubMed
    Score: 0.142
  23. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):3461-76.
    View in: PubMed
    Score: 0.135
  24. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015 Aug 15; 21(16):3705-15.
    View in: PubMed
    Score: 0.128
  25. Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. Blood. 2015 Feb 12; 125(7):1126-36.
    View in: PubMed
    Score: 0.125
  26. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92.
    View in: PubMed
    Score: 0.117
  27. Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Apr; 55(4):899-910.
    View in: PubMed
    Score: 0.115
  28. DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells. Leuk Lymphoma. 2014 Apr; 55(4):876-83.
    View in: PubMed
    Score: 0.114
  29. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol. 2010 Dec 15; 80(12):1936-45.
    View in: PubMed
    Score: 0.092
  30. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 2010 Aug 12; 116(6):886-92.
    View in: PubMed
    Score: 0.091
  31. Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. Br J Haematol. 2009 Nov; 147(3):297-307.
    View in: PubMed
    Score: 0.087
  32. Mcl-1: the 1 in CLL. Blood. 2008 Nov 01; 112(9):3538-40.
    View in: PubMed
    Score: 0.082
  33. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007 Sep 15; 110(6):1762-9.
    View in: PubMed
    Score: 0.074
  34. Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents. J Med Chem. 2018 10 25; 61(20):9132-9145.
    View in: PubMed
    Score: 0.041
  35. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112.
    View in: PubMed
    Score: 0.037
  36. Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells. Eur J Med Chem. 2017 Jun 16; 133:197-207.
    View in: PubMed
    Score: 0.037
  37. Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes. J Med Chem. 2014 Jun 12; 57(11):4498-510.
    View in: PubMed
    Score: 0.030
  38. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8.
    View in: PubMed
    Score: 0.029
  39. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9.
    View in: PubMed
    Score: 0.025
  40. Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs. J Am Chem Soc. 2011 Dec 07; 133(48):19278-81.
    View in: PubMed
    Score: 0.025
  41. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50.
    View in: PubMed
    Score: 0.022
  42. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.